Method of therapy selection for patient suffering from glioblastoma
The present invention relates to method of therapy selection for patient suffering from glioblastoma. Using in vitro and in vivo approaches, the inventors demonstrated the critical role of CD90 in GBM migration/invasion. They showed that CD90 signaling though SRC, FAK and RhoA promotes cell migration and importantly, that high CD90 expression impacts on the cell response to the SRC inhibitor dasatinib. In particular, the present invention relates to a method for predicting whether a subject will be eligible to a treatment with a drug selected from the group consisting of SRC inhibitor, FAK inhibitor or RhoA inhibitor by determining the expression level of CD90 in a sample obtained from the subject.
1. A method of treating glioblastoma with a drug selected from the group consisting of SRC inhibitor, FAK inhibitor and RhoA inhibitor in an eligible subject in need thereof comprising
i) determining the expression level of CD90 in a sample comprising glioblastoma cells obtained from the subject,
ii) comparing the expression level determined at step i) with a predetermined reference level,
iii) identifying that the subject is eligible for treatment when the expression level determined at step i) is higher than the predetermined reference level, and
iv) administering a therapeutically effective amount of the drug selected from the group consisting of SRC inhibitor, FAK inhibitor and RhoA inhibitor to the subject, wherein the therapeutically effective amount is sufficient to inhibit at least one property of the glioblastoma cells selected from the group consisting of cell adhesion, migration and invasion.
2. The method of claim 1 wherein the SRC inhibitor is dasatinib.
3. The method of claim 1 wherein the sample comprising glioblastoma cells further comprises differentiated glioblastoma tumor cells.
4. A method for treating glioblastoma multiforme (GBM) with dasatinib in an eligible subject in need thereof, comprising
i) determining the expression level of CD90 in a sample comprising differentiated glioblastoma cells obtained from the subject,
ii) comparing the expression level determined at step i) with a predetermined reference level,
iii) identifying that the subject is eligible for treatment when the expression level determined at step i) is higher than the predetermined reference level, and
iv) administering a therapeutically effective amount of the dasatinib to the subject, wherein the therapeutically effective amount is sufficient to inhibit at least one property of the differentiated glioblastoma cells selected from the group consisting of cell adhesion, migration and invasion.
5. The method of claim 4 , wherein dasatinib is administered as the sole agent for treating GBM.